Last reviewed · How we verify
celebrex
At a glance
| Generic name | celebrex |
|---|---|
| Also known as | celecoxib, Celecoxib (brand name), Celecoxib, chemical drug, celecoxib placebo |
| Sponsor | POZEN |
| Target | 3-phosphoinositide-dependent protein kinase 1, Adenosine receptor A3, Cytochrome c oxidase subunit 2 |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Approved indications
- Acute postoperative pain
- Ankylosing spondylitis
- Dysmenorrhea
- Juvenile rheumatoid arthritis
- Osteoarthritis
- Rheumatoid arthritis
Common side effects
- Headache
- Dyspepsia
- Upper Respiratory Infection
- Diarrhea
- Sinusitis
- Abdominal Pain
- Nausea
- Injury-Accidental
- Back Pain
- Pharyngitis
- Insomnia
- Flatulence
Serious adverse events
- Myocardial Infarction
- Coronary Artery Disorder
- Angina Pectoris
- Aggravated Hypertension
- Melena
- Esophagitis
- Gastritis
- Diverticulitis
- Hypersensitivity
Key clinical trials
- Examining Analgesic Synergy and Efficacy in Trauma Care (PHASE4)
- Nonopioid Analgesia After Anterior Cruciate Ligament Reconstruction (PHASE2, PHASE3)
- Safety of Fluvastatin-Celebrex Association in Low-grade and High Grade Optico-chiasmatic Gliomas (PHASE1)
- I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients (PHASE2)
- Serplulimab Combined With CAPEOX + Celecoxib as Neoadjuvant Treatment for Locally Advanced Rectal Cancer (PHASE2)
- Neoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon Cancer (PHASE2)
- Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors (PHASE2)
- Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- celebrex CI brief — competitive landscape report
- celebrex updates RSS · CI watch RSS
- POZEN portfolio CI